164 related articles for article (PubMed ID: 8842603)
1. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group.
Goldberg RB; Holvey SM; Schneider J
Diabetes Care; 1996 Aug; 19(8):849-56. PubMed ID: 8842603
[TBL] [Abstract][Full Text] [Related]
2. Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group.
Rosenstock J; Samols E; Muchmore DB; Schneider J
Diabetes Care; 1996 Nov; 19(11):1194-9. PubMed ID: 8908379
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
Kadowaki T; Kondo K
Diabetes Obes Metab; 2014 May; 16(5):418-25. PubMed ID: 24205974
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
Luis Bautista J; Bugos C; Dirnberger G; Atherton T
Clin Ther; 2003 Jan; 25(1):194-209. PubMed ID: 12637120
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.
Simonson DC; Kourides IA; Feinglos M; Shamoon H; Fischette CT
Diabetes Care; 1997 Apr; 20(4):597-606. PubMed ID: 9096986
[TBL] [Abstract][Full Text] [Related]
6. A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful.
Schade DS; Jovanovic L; Schneider J
J Clin Pharmacol; 1998 Jul; 38(7):636-41. PubMed ID: 9702849
[TBL] [Abstract][Full Text] [Related]
7. A double-masked placebo-controlled trial assessing effects of various doses of BTS 67,582, a novel insulinotropic agent, on fasting hyperglycemia in NIDDM patients.
Skillman CA; Raskin P
Diabetes Care; 1997 Apr; 20(4):591-6. PubMed ID: 9096985
[TBL] [Abstract][Full Text] [Related]
8. Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial.
Østoft SH; Bagger JI; Hansen T; Pedersen O; Faber J; Holst JJ; Knop FK; Vilsbøll T
Diabetes Care; 2014 Jul; 37(7):1797-805. PubMed ID: 24929431
[TBL] [Abstract][Full Text] [Related]
9. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.
Ahrén B; Johnson SL; Stewart M; Cirkel DT; Yang F; Perry C; Feinglos MN;
Diabetes Care; 2014 Aug; 37(8):2141-8. PubMed ID: 24898304
[TBL] [Abstract][Full Text] [Related]
10. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group.
Riddle MC; Schneider J
Diabetes Care; 1998 Jul; 21(7):1052-7. PubMed ID: 9653594
[TBL] [Abstract][Full Text] [Related]
11. Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus.
Sonnenberg GE; Garg DC; Weidler DJ; Dixon RM; Jaber LA; Bowen AJ; DeChemey GS; Mullican WS; Stonesifer LD
Ann Pharmacother; 1997 Jun; 31(6):671-6. PubMed ID: 9184703
[TBL] [Abstract][Full Text] [Related]
12. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors.
Derosa G; Mugellini A; Ciccarelli L; Crescenzi G; Fogari R
Clin Ther; 2003 Feb; 25(2):472-84. PubMed ID: 12749508
[TBL] [Abstract][Full Text] [Related]
13. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
[TBL] [Abstract][Full Text] [Related]
14. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study.
Kim SS; Kim IJ; Lee KJ; Park JH; Kim YI; Lee YS; Chung SC; Lee SJ
J Diabetes; 2017 Apr; 9(4):412-422. PubMed ID: 27229178
[TBL] [Abstract][Full Text] [Related]
16. [Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride].
Strojek K; Yoon KH; Hruba V; Elze M; Langkilde AM; Parikh S
Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S16-26. PubMed ID: 23529567
[TBL] [Abstract][Full Text] [Related]
17. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study.
Lam KS; Tiu SC; Tsang MW; Ip TP; Tam SC
Diabetes Care; 1998 Jul; 21(7):1154-8. PubMed ID: 9653611
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of efficacy and tolerability of glimepiride and metformin combination: a multicentric study in patients with type-2 diabetes mellitus, uncontrolled on monotherapy with sulfonylurea or metformin.
Pareek A; Chandurkar NB; Salkar HR; Borkar MS; Tiwari D
Am J Ther; 2013 Jan; 20(1):41-7. PubMed ID: 21326082
[TBL] [Abstract][Full Text] [Related]
19. A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8).
Dungan KM; Weitgasser R; Perez Manghi F; Pintilei E; Fahrbach JL; Jiang HH; Shell J; Robertson KE
Diabetes Obes Metab; 2016 May; 18(5):475-82. PubMed ID: 26799540
[TBL] [Abstract][Full Text] [Related]
20. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.
Tan M; Johns D; González Gálvez G; Antúnez O; Fabián G; Flores-Lozano F; Zúñiga Guajardo S; Garza E; Morales H; Konkoy C; Herz M;
Clin Ther; 2004 May; 26(5):680-93. PubMed ID: 15220012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
